Pediatric Oncology

A first-ever pediatric blue book has been developed as part of the fifth edition of the WHO Classification of Tumors series.

Commercially available chimeric antigen receptor T cells for acute myeloid leukemia could be just a few years away, according to a presenter at the inaugural Personalizing Pediatric Cancer Care Summit.

National Cancer Institute announced the launch of a program that offers molecular characterization of childhood cancers.

James Amatruda, MD, PhD, never set out to become a fish farmer.

The addition of the novel monoclonal antibody hu14.18K322A to induction chemotherapy significantly improved outcomes among children with newly diagnosed high-risk neuroblastoma, according to phase 2 study results.

“I want you to be honest with me — how long do I have left?”

It’s the news no patient with cancer wants to hear: There’s nothing more we can do for you.

Adolescent and young adult patients with central nervous system tumors who lived farther from the reporting hospital had a lower risk for death than those who lived closer, according to study results published in Journal of Neuro-Oncology.

More than 60% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia achieved initial complete remission after receiving an investigational chimeric antigen receptor T-cell therapy, phase 1/phase 2 study results showed.

The Fred Hutch/University of Washington Cancer Consortium has announced new leadership.